United Therapeutics

Towana Looney received a gene-edited pig kidney transplant at NYU Langone Health, marking a breakthrough in xenotransplantation. The procedure, involving 10 gene edits, aims to address the organ supply crisis. Looney, who had been on dialysis for years, is now in better health and the first to receive such a kidney.

NYU Langone Health transplanted a genetically modified pig kidney into a 53-year-old woman, Towana Looney, for the third time. Looney, who had been on dialysis for over eight years, was discharged from the hospital and is recovering well. The kidney came from a pig with 10 DNA alterations, including removal of immune-triggering genes. This follows two previous pig kidney transplants, one of which failed due to inadequate blood flow. Xenotransplantation remains experimental and is only available to critically ill patients under the FDA's compassionate use program.

United Therapeutics announced the first UKidney transplant into a living person on Nov 25, 2024, following successful UHeart and UThymoKidney transplants. The patient, Towana Looney, had kidney failure and couldn't find a suitable donor. The UKidney, a pig kidney with 10 gene edits, aims to address organ shortages.

Two European studies highlight the need for better diagnosis and treatment of pulmonary hypertension associated with interstitial lung disease (ILD). The first study, published in *Pulmonary Circulation*, found that early recognition of symptoms could be life-changing, with shortness of breath being the most distressing symptom. The second study, published in *ERJ Open Research*, revealed significant unmet needs in managing this rare disease, emphasizing the need for comprehensive screening, diagnostic protocols, and effective treatments.

Field medical education and pre-launch scientific outreach improve treatment adoption. Medical conferences amplify scientific information and are crucial for engaging thought leaders. Biopharma companies must choose relevant events, consider broader HCP audiences, and engage early-career HCPs for greater impact. Personalized KOL interactions and coordinated company approaches are essential. Monitoring digital reactions to competitor presentations is vital for understanding market position. Optimizing medical congress participation fosters collaborations and advances patient care.

A New Jersey federal court awarded Sandoz over $70 million in its lawsuit against United Therapeutics for blocking the sale of a generic hypertension drug, finding that Sandoz lost more than $137 million in profits as a result of United Therapeutics breaching a 2015 settlement agreement.

AbbVie, a pharmaceutical firm with strong immunology and oncology portfolios, is compared against key competitors in the Biotechnology industry. Analysis reveals AbbVie's PE ratio is low, suggesting potential undervaluation, while its high PB ratio indicates overvaluation based on book value. A low PS ratio implies undervaluation based on sales. AbbVie's high ROE, EBITDA, and gross profit highlight strong profitability and operational efficiency, but low revenue growth indicates challenges in market expansion.

United Therapeutics Corporation's websites contain forward-looking statements about product pipeline, R&D, and regulatory approvals, subject to risks and uncertainties. Information is current as of the presented date, and not updated. Clinical data on the website may not align with FDA-approved labeling and is not medical advice. FDA-approved product info is available at specific links.

U.S. Supreme Court denied United Therapeutics' appeal, affirming all claims of Patent No. 10,716,793 are invalid. Liquidia's decisions on non-infringement of three patents are final. FDA granted tentative approval for YUTREPIA inhalation powder for PAH and PH-ILD, with final approval pending after Tyvaso DPI exclusivity expires in 2025.